Who Owns Sarepta Therapeutics Company?

Sarepta Therapeutics Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Sarepta Therapeutics?

In June 2024 an FDA label expansion for Elevidys sharply affected Sarepta Therapeutics’ valuation and raised ownership questions for investors and patients. Founded in 1980 and now based in Cambridge, MA, Sarepta focuses on precision genetic medicines across RNA, gene therapy, and gene editing.

Publicly traded (NASDAQ: SRPT), Sarepta’s shareholder base is mainly institutional, with market cap in the low-to-mid $10 billions in 2024–2025; ownership shifts drive strategy, R&D priorities, pricing, and access. See Sarepta Therapeutics Porter's Five Forces Analysis

Sarepta Therapeutics began as AntiVirals, Inc. in Corvallis, Oregon (1980), later AVI BioPharma, and rebranded to Sarepta Therapeutics in 2012; early ownership was research-focused with academic collaborators, and detailed founder cap-table records are limited publicly. Over successive 1980s–2000s financings the company diluted initial stakes as it transitioned to a public, antisense/RNA therapeutics platform.

Origins and Name Changes

Founded as AntiVirals, Inc. (1980) in Corvallis, the business became AVI BioPharma and adopted the Sarepta Therapeutics name in 2012.

Scientific Nucleus

Early scientific leadership was tied to Oregon academic collaborators; intellectual contributions drove initial R&D but public equity records on founders are sparse.

Financing and Dilution

1980s–1990s venture financings and later public raises dispersed early ownership, a pattern typical of biotech formation and growth-stage capital needs.

Public Market Transition

By the 2000s equity was meaningfully syndicated among public investors, shifting control away from private founders toward institutional holders.

Strategic Pivot to DMD

Pivotal advances in exon-skipping refocused the company on Duchenne muscular dystrophy (DMD), aligning governance and capital toward rare-disease genetic medicines.

Founder Stakes by 2012

Original founder stakes were substantially diluted by the 2012 rebrand; institutional and public shareholders became the primary owners as programs matured.

Public filings show that by mid-2024 institutional investors held a majority of publicly available shares—Vanguard, BlackRock, and other mutual/ETF managers commonly appear among top holders—while insider ownership remained under 10% aggregate; detailed early founder equity splits and vesting terms are not publicly disclosed.

Key facts and implications

Founders and early ownership shaped Sarepta's scientific direction but were diluted through commercialization-focused financing rounds and public listings; institutional investors now dominate the ownership landscape.

• Original company formed in 1980 as AntiVirals, Inc.
• Renamed to Sarepta Therapeutics in 2012
• Institutional ownership majority by 2024 (e.g., Vanguard, BlackRock reported among top holders)
• Insider ownership aggregated typically below 10% in recent SEC filings

For ownership structure context and revenue model connections see Revenue Streams & Business Model of Sarepta Therapeutics

Sarepta Therapeutics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key regulatory approvals, the 2019 Roche collaboration and equity purchase, and the 2023–2024 Elevidys approvals and label expansion materially reshaped Sarepta Therapeutics ownership—shifting the stock from micro/mid-cap biotech concentration toward a widely held, institutionally dominated register and greater index-fund influence.

The ownership evolution produced a register dominated by large asset managers and passive funds, reducing founder/insider concentration and aligning governance with large-cap biotech norms.

Major holders and stakes (2024–2025 filings)

Institutional ownership is the primary driver of voting power; Vanguard and BlackRock typically lead, with several asset managers holding meaningful positions.

• The Vanguard Group — commonly in the high single-digit percent range of outstanding shares
• BlackRock, Inc. — commonly in the high single-digit percent range
• State Street, Wellington Management, T. Rowe Price, Fidelity (FMR), Baillie Gifford — each generally in low-to-mid single-digit percentages
• Roche Holding AG — strategic mid-single-digit stake from the 2019 transaction; remains a notable strategic holder
• Insider ownership — modest; aggregate executive/director holdings historically under 2% (typical for mid-cap U.S. biopharma peers)

For a deeper look at strategic rationale and commercialization links between ownership and ex-U.S. rollout of gene therapies, see Growth Strategy of Sarepta Therapeutics.

Sarepta Therapeutics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Sarepta Therapeutics' board combines executive leadership and a majority of independent directors with expertise in biopharma, commercialization, finance, and R&D; Douglas S. Ingram serves as CEO and director, and committee chairs cover audit, compensation, and nominating/governance consistent with U.S. public-company norms.

Sarepta maintains a single-class common equity structure with one-share-one-vote; there are no disclosed dual-class or super-voting founder shares or golden shares, so voting power is proportional to share ownership and concentrated among large institutional and strategic holders.

Board balance and voting influence

Institutional investors hold the largest voting blocs, shaping proxy outcomes and governance priorities; director slates are set annually and reflect a mix of operators and investor-aligned independents.

• Single-class common equity: one-share-one-vote
• Majority independent board with CEO as director
• No public record of dual-class, super-voting, or golden shares
• Investor engagement focuses on clinical progress, manufacturing scale-up, and Elevidys access

As of the 2024–2025 proxy cycle institutional ownership remained significant: Vanguard and BlackRock were among top holders with combined stake estimates often exceeding 20% in filings; Sarepta shareholder concentration means votes by major shareholders materially affect outcomes and director elections — see Mission, Vision & Core Values of Sarepta Therapeutics for related company context.

Sarepta Therapeutics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent regulatory wins (Elevidys approval in 2023 and a June 2024 label expansion) and subsequent commercial progress pushed trading volumes and institutional inflows, moving Sarepta Therapeutics into a low-to-mid $10+ billion market-cap range at points in 2024–2025 and solidifying its place in core healthcare indices and growth portfolios.

Quarterly 13F filings and company disclosures show Vanguard, BlackRock, and State Street among the largest passive holders, with active managers like Wellington, T. Rowe, FMR, and Baillie Gifford also prominent; Roche’s strategic position remains material and visible in filings, and any changes can affect AGM dynamics and M&A/partnership prospects.

Trading and Market Cap Movement

Elevidys-related approvals and label expansion in 2023–2024 drove spikes in trading volume and pushed market cap into the low-to-mid $10B+ band at times in 2024–2025.

Financing and Share Count

Periodic equity and convertible debt financings funded manufacturing and studies, producing moderate dilution typical for commercial gene-therapy companies during 2024–2025.

Institutional Concentration

Institutional ownership remains dominant (commonly around 85–95% of tradable float among peers), with Vanguard, BlackRock, and State Street as leading passive holders and active managers holding meaningful stakes.

Strategic and Analyst Focus

Roche’s strategic equity from 2019 is a key anchor; analysts in 2024–2025 note potential for further consolidation of Sarepta Therapeutics ownership if Elevidys penetration and ex-U.S. ramps via Roche broaden.

For background on company origins and earlier ownership shifts see Brief History of Sarepta Therapeutics.

Sarepta Therapeutics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔